Skip to main content
. 2021 Jul 2;25(9):2020–2038. doi: 10.1002/ejp.1818

TABLE 4.

Overview of primary care, secondary care and prescribed medication healthcare utilization and associated costs

Resources Costs a
Intervention Control Intervention Control p‐value
Number Mean (SD) Number Mean (SD)
Primary Care
Physiotherapy 125 7.1 (8.5) 141 6.4 (6.8) 13.08 [12.76–13.41] 14.26 [13.91–14.61] .000
General practitioner 159 8.7 (9.2) 148 7.6 (6.2) 12.67 [12.31–13.03] 13.91 [13.47–14.35] .000
Chiropractor 18 4.7 (3.8) 16 5.9 (4.7) 7.02 [6.31–7.74] 6.38 [5.77–6.99] .178
Rehabilitation (municipality) 9 17.6 (16.2) 10 19.1 (15.5) 16.00 [16.00–16.00] 16.00 [16.00–16.00] NA
Other primary care contacts b 11 2.8 (1.3) 8 1.9 (1.1) 41.76 [31.95–51.57] 50.20 [33.24–67.15] .381
Secondary Care
Spine centre 9 2.9 (2.2) 18 3.0 (2.8) 489.87 [−81.19–1060.93] 470.03 [89.83–850.24] .954
MRI 31 1.2 (0.4) 29 1.1 (0.4) 365.29 [290.73–439.85] 328.55 [257.54–399.56] .485
CT imaging 8 1.3 (0.7) 6 1.3 (0.8) 439.12 [74.86–803.38] 490.52 [35.60–945.43] .862
X‐ray 55 1.6 (1.1) 53 1.5 (0.8) 310.06 [46.36–573.77] 981.42 [90.51–1872.33] .069
Other secondary care contacts c 70 4.9 (5.7) 67 4.7 (5.4) 440.91 [335.13–546.70] 455.25 [341.07–569.42] .857
Medication
Prescribed non‐opioid analgesics 76 3.59 (3.55) 72 3.78 (4.70) 7.84 [7.24–8.45] 7.03 [6.49–7.58] .051
Prescribed opioid analgesics 34 5.65 (10.45) 27 4.96 (5.40) 7.71 [6.25–9.17] 16.61 [12.85–20.37] .000
Prescribed tricyclic medication d 21 5.10 (5.01) 27 7.26 (6.63) 22.45 [14.96–29.94] 30.85 [23.25–38.46] .133

The table shows mean number of treatments (and standard deviation) for participants in each treatment group. For all participants who has a registered treatment in the Danish Nationwide Patient Registry.

Costs reflect the mean regional healthcare expenditure in EUR for each treatment given in the two treatments groups.

a

€.

b

Rheumatologist, Neurologist.

c

e.g. emergency care, surgery (only one patient from the control arm ended up having back surgery).

d

used for neurogenic pain.